Prio Wealth Limited Partnership’s Vertex Pharmaceuticals VRTX Stock Holding History

Prio Wealth Limited Partnership’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$391K	Hold	841	–	–	0.01%	211
2024 Q2	$394K	Hold	841	–	–	0.01%	205
2024 Q1	$352K	Sell	841 -2	-0.2%	-$845	0.01%	217
2023 Q4	$343K	Sell	843 -4	-0.5%	-$1.48K	0.01%	204
2023 Q3	$295K	Buy	847 +274	+48%	+$95.8K	0.01%	212
2023 Q2	$202K	Buy	+573	New	+$193K	0.01%	245
2020 Q4	–	Sell	-873	Closed	-$238K	–	279
2020 Q3	$238K	Buy	873 +184	+27%	+$50.8K	0.01%	239
2020 Q2	$200K	Buy	+689	New	+$187K	0.01%	251

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Prio Wealth Limited Partnership's VRTX Position: Q3 2024 in Review

Prio Wealth Limited Partnership held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2024 at 841 shares worth $391K. The position accounts for 0.01% of the portfolio, ranked #211.

Prio Wealth Limited Partnership first reported a position in VRTX in Q2 2020 and has held it in 8 quarters since. The position peaked at $394K in Q2 2024. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

Prio Wealth Limited Partnership held 841 shares of Vertex Pharmaceuticals worth $391K as of Q3 2024.
Prio Wealth Limited Partnership left its Vertex Pharmaceuticals share count unchanged in Q3 2024.
Vertex Pharmaceuticals made up 0.01% of Prio Wealth Limited Partnership's portfolio in Q3 2024, its #211 holding.
Prio Wealth Limited Partnership first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 8 quarters since.
Prio Wealth Limited Partnership's Vertex Pharmaceuticals position peaked at $394K in Q2 2024.
1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Prio Wealth Limited Partnership's 13F filing for Q3 2024, filed 21 Oct 2024.